KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to 40.91%.

  • Rigel Pharmaceuticals' EBITDA Margin rose 155000.0% to 40.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.17%, marking a year-over-year increase of 361400.0%. This contributed to the annual value of 13.49% for FY2024, which is 310300.0% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' EBITDA Margin stood at 40.91%, which was up 155000.0% from 60.09% recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' EBITDA Margin registered a high of 60.09% during Q2 2025, and its lowest value of 156.92% during Q1 2022.
  • For the 5-year period, Rigel Pharmaceuticals' EBITDA Margin averaged around 20.8%, with its median value being 15.87% (2023).
  • Over the last 5 years, Rigel Pharmaceuticals' EBITDA Margin had its largest YoY gain of 1090000bps in 2022, and its largest YoY loss of -2084600bps in 2022.
  • Rigel Pharmaceuticals' EBITDA Margin (Quarter) stood at 104.94% in 2021, then surged by 104bps to 4.05% in 2022, then surged by 35bps to 5.49% in 2023, then soared by 426bps to 28.92% in 2024, then skyrocketed by 41bps to 40.91% in 2025.
  • Its last three reported values are 40.91% in Q3 2025, 60.09% for Q2 2025, and 23.95% during Q1 2025.